Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

1. Gopal, A.K.
2. Schuster, S.J.
3. Fowler, N.H.
4. Trotman, J.
5. Hess, G.
6. Hou, J.-Z.
7. Yacoub, A.
8. Lill, M.
9. Martin, P.
10. Vitolo, U.
11. Spencer, A.
12. Radford, J.
13. Jurczak, W.
14. Morton, J.
15. Caballero, D.
16. Deshpande, S.
17. Gartenberg, G.J.
18. Wang, S.-S.
19. Damle, R.N.
20. Schaffer, M.
21. Balasubramanian, S.
22. Vermeulen, J.
23. Cheson, B.D.
24. Salles, G.